---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic impact of diagnostic testing"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Economic impact of diagnostic testing. Topics: Genetic testing: cost and limited routine necessity, Medicare payment rates for complement antigen and functional assays, Functional C1 inhibitor assay as the single initial test and expected effect on diagnostic costs, Genetic testing for hereditary angioedema with normal C1 inhibitor and cascade family testing, and 3 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/economic-impact-of-diagnostic-testing"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic impact of diagnostic testing

<a id="heading-2.2.1.8.4"></a>

## 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

### Genetic testing: cost and limited routine necessity

> “genetic testing can be costly, time-consuming, and rarely necessary.”

Source: [Henao et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4859422/)

<a id="topic-2.2.1.8.4-2"></a>

### Medicare payment rates for complement antigen and functional assays

> “2026,86160,,20260101,N,00012.00,Complement antigen”
> “2026,86161,,20260101,N,00012.00,Complement/function activity”

Source: [CMS Clinical Laboratory Fee Schedule (2026)](https://www.cms.gov/files/zip/26clabq4.zip)

<a id="topic-2.2.1.8.4-3"></a>

### Functional C1 inhibitor assay as the single initial test and expected effect on diagnostic costs

> “This approach involves performing only the C1-INH functional assay whenever this test is available and reliable, rather than following the traditional recommendation of conducting all 3 tests (C1-INH levels, C1-INH functional assay, and C4 level), potentially reducing diagnostic costs (Fig. 5).”
> “The C1-INH antigenic assay is widely available, simple to perform, and generally accessible.”
> “Functional activity testing of C1-INH and genetic testing are both rarely available in low- and middle-income countries, and genetic testing is often expensive in high-income countries.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.8.4-4"></a>

### Genetic testing for hereditary angioedema with normal C1 inhibitor and cascade family testing

> “We recommend genetic testing for HAE-nC1-INH in patients for whom there is high clinical suspicion of HAE and who have normal C1-INH functional assay results.”
> “Cascade screening refers to the process of sequentially testing close blood relatives, beginning with first-degree relatives and extending to siblings, parents, and children when a family member is found to be affected.”
> “This approach helps reduce costs, improves management of currently asymptomatic but affected individuals, and alleviates anxiety for unaffected family members.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.8.4-5"></a>

### Cost of sequential biochemical and genetic testing and sample transport

> “Firstly, the use of a series of multiple tests from the initial C4 and C1-INH levels, followed by C1-INH function, and in equivocal cases or suspected HAE-nC1INH, genetic tests, is considerably costly.”
> “In regions lacking local laboratory capacity, samples must be shipped to external reference centres, incurring further costs and diagnostic delays [37].”
> “C1-INH protein is labile in vitro; unless testing is performed within hours, samples require on-site centrifugation and storage at − 20 °C, necessitating an expensive cold chain for transport [38, 39].”

Source: [Leung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13630838/)

<a id="topic-2.2.1.8.4-6"></a>

### Effect of cascade family screening on hereditary angioedema-related costs: prospective screening program

> “Prospective data on clinical, psychological, and HAE-related outcomes were collected at baseline and 1-year follow-up.”
> “Potential HAE relatives were screened through the CFS approach.”
> “Of 179 relatives, 53% were contactable, 67% of whom consented to screening.”
> “Twenty-nine patients (46%) were newly given the diagnosis of HAE; half were symptomatic at baseline (52%).”
> “By extrapolation, CFS led to a reduction of at least HK $1,200 (US $153) in HAE-related costs per patient per year.”
> “Screening using a greater than suggested C4 cutoff of 22.9 mg/dL yielded superior sensitivity (100%) and specificity (77%).”

Source: [Wong et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35964924/)

<a id="topic-2.2.1.8.4-7"></a>

### Diagnostic delay and its association with direct and indirect costs

> “In total, 65 articles that met the search inclusion criteria reported 10,310 patients with HAE, of whom 5861 were female patients.”
> “The mean or median delay from the first onset of a symptom of HAE to confirmed diagnosis ranged from 3.9 to 26 years.”
> “The major components accounting for the increase in economic costs were hospitalization, treatments, unnecessary surgeries, doctors’ visits, specialist services, and nurse costs.”
> “However, there is considerable evidence indicating that delayed diagnosis of HAE is associated with decreased physical function, increased risk of mortality, negative psychological impact, and higher direct and indirect costs.”

Source: [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
